CVS Health Files 8-K: Other Events & Financials
Ticker: CVS · Form: 8-K · Filed: May 8, 2024 · CIK: 64803
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
CVS filed an 8-K on 5/7 for other events and financials. All good.
AI Summary
CVS Health Corporation filed an 8-K on May 7, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at One CVS Drive, Woonsocket, Rhode Island, 02895.
Why It Matters
This 8-K filing provides an update on CVS Health's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate events and financial statements, not indicating any immediate or significant risks.
Key Numbers
- 001-01011 — Commission File Number (Identifies the company's filing with the SEC)
- 05-0494040 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- CVS HEALTH Corporation (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- One CVS Drive, Woonsocket, Rhode Island 02895 (location) — Principal executive offices
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text does not specify the 'Other Events' beyond indicating that this section is part of the filing.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on May 7, 2024.
What is CVS Health Corporation's principal executive office address?
The principal executive offices are located at One CVS Drive, Woonsocket, Rhode Island 02895.
Under which state is CVS Health Corporation incorporated?
CVS Health Corporation is incorporated in Delaware.
What is the Commission File Number for CVS Health Corporation?
The Commission File Number for CVS Health Corporation is 001-01011.
Filing Stats: 722 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-05-08 16:40:04
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share CVS New York Stock Exchan
- $1,000,000,000 — d to issue and sell to the Underwriters $1,000,000,000 aggregate principal amount of the Compa
- $1,250,000,000 — nior Notes due 2031 (the "2031 Notes"), $1,250,000,000 aggregate principal amount of the Compa
- $750,000,000 — nior Notes due 2034 (the "2034 Notes"), $750,000,000 aggregate principal amount of the Compa
- $4,950,251,518 — yable by the Company, are approximately $4,950,251,518. A copy of the Underwriting Agreement i
Filing Documents
- d778123d8k.htm (8-K) — 28KB
- d778123dex11.htm (EX-1.1) — 196KB
- g778123g0508120412215.jpg (GRAPHIC) — 2KB
- 0001193125-24-134280.txt ( ) — 388KB
- cvs-20240507.xsd (EX-101.SCH) — 3KB
- cvs-20240507_lab.xml (EX-101.LAB) — 17KB
- cvs-20240507_pre.xml (EX-101.PRE) — 11KB
- d778123d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The exhibits to this Current Report on Form 8-K are as follows: INDEX TO EXHIBITS Exhibit Description 1.1 Underwriting Agreement dated May 7, 2024, among CVS Health Corporation and BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several Underwriters named in Schedule I thereto. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CVS HEALTH CORPORATION Date: May 8, 2024 By: /s/ Thomas F. Cowhey Thomas F. Cowhey Executive Vice President and Chief Financial Officer